Long-term clinical trial safety experience with the inactivated split influenza vaccine, Vaxigrip®

Vaccine

Volumn 24, Issue 10, 2006, Pages 1586-1592

  Delore, Valentine ^a   Salamand, Camille ^a   Marsh, Grenville ^a   Arnoux, Sabine ^a   Pepin, Stephanie ^a   Saliou, Pierre ^b  

^a SANOFI PASTEUR   (France)

^b Ancien Pres Soc Pathol Exotique   (France)

Author keywords

Clinical trials; Inactivated influenza vaccine; Vaccine safety

Indexed keywords

INACTIVATED VACCINE; INFLUENZA VACCINE; ISTIVAC;

ADULT; AGED; ARTHRALGIA; ARTICLE; ASTHENIA; CHILD; CLINICAL PRACTICE; CLINICAL TRIAL; DRUG TOLERABILITY; DRUG USE; ECCHYMOSIS; ERYTHEMA; FEMALE; FEVER; HEADACHE; HUMAN; HYPERHIDROSIS; INFANT; INFLUENZA; INJECTION SITE EDEMA; INJECTION SITE PAIN; INJECTION SITE PRURITUS; MAJOR CLINICAL STUDY; MALAISE; MALE; MYALGIA; PRIORITY JOURNAL; SHIVERING; SKIN INDURATION; SKIN REDNESS; SYSTEMIC DISEASE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS; HUMANS; INFANT; INFLUENZA VACCINES; MIDDLE AGED; SAFETY; VACCINES, INACTIVATED;

EID: 32544434766     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2005.10.008     Document Type: Article

References (18)

1. K.G. Nicholson, J.M. Wood, and M. Zambon Influenza Lancet 362 9397 2003 1733 1745
2. H.S. Izurieta, W.W. Thompson, P. Kramarz, D.K. Shay, R.L. Davis, and F. DeStefano Influenza and the rates of hospitalization for respiratory disease among infants and young children N Engl J Med 342 4 2000 232 239
3. S.C. Wood, A. Alexseiv, and V.H. Nguyen Effectiveness and economical impact of vaccination against influenza among a working population in Moscow Vaccine 17 Suppl 3 1999 S81 S87
4. K.L. Nichol, K.P. Mallon, and P.M. Mendelman Cost benefit of influenza vaccination in healthy, working adults: an economic analysis based on the results of a clinical trial of trivalentlive attenuated influenza virus vaccine Vaccine 21 17-18 2003 2216 2226
5. R.J. Cox, K.A. Brokstad, and P. Ogra Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines Scand J Immunol 59 1 2004 1 15
6. F.L. Ruben Inactivated influenza virus vaccines in children Clin Infect Dis 38 5 2004 678 688
7. K. Fukuda, R.A. Levandowski, C.B. Bridges, and N.J. Cox Inactivated influenza vaccines S.A. Plotkin W.A. Orenstein Vaccines 2004 Philadelphia PA, Saunders 339 370
8. Influenza vaccines. Recommendations for the use of inactivated influenza vaccines and other preventive measures Wkly Epidemiol Rec 75 35 2000 281 288
9. Committee for Proprietary Medicinal Products (CPMP). Note for guidance on harmonisation of requirements for influenza vaccines. (CPMP/BWP/214/96). 1997.
10. B. Lina, M.A. Fletcher, M. Valette, P. Saliou, and M. Aymard A Triton X-100-split virion influenza vaccine is safe and fulfills the Committee for Proprietary Medicinal Products (CPMP) recommendations for the European Community for Immunogenicity, in Children, Adults and the Elderly Biologicals 28 2000 95 103
11. M. Gonzalez, M.C. Pirez, E. Ward, H. Dibarboure, A. Garcia, and H. Picolet Safety and immunogenicity of a paediatric presentation of an influenza vaccine Arch Dis Child 83 6 2000 488 491
12. A. Morales, S.J. Arias, Y. Salazar, A. Garcia, S. Amoux, and A. Arancibia A randomized controlled trial comparing split and subunit influenza vaccines in adults in Colombia Medicina (B Aires) 63 3 2003 197 204
13. S.A. Harper, K. Fukuda, T.M. Uyeki, N.J. Cox, and C.B. Bridges Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP) MMWR Recomm Rep 53 RR-6 2004 l 40
14. E.K. France, J.M. Glanz, S. Xu, R.L. Davis, S.B. Black, and H.R. Shinefield Safety of the trivalent inactivated influenza vaccine among children: a population-based study Arch Pediatr Adolesc Med 158 11 2004 1031 1036
15. S. Spila-Alegiani, S. Salmaso, M.C. Rota, A.E. Tozzi, and R. Raschetti Reactogenicity in the elderly of nine commercial influenza vaccines: results from the Italian SVEVA study. Study for the evaluation of adverse events of influenza vaccination Vaccine 17 15-16 1999 1898 1904
16. S. Squarcione, S. Sgricia, L.R. Biasio, and E. Perinetti Comparison of the reactogenicity and immunogenicity of a split and a subunit-adjuvanted influenza vaccine in elderly subjects Vaccine 21 11-12 2003 1268 1274
17. N.W. Hehme, W. Kiinzel, F. Petschke, G. Turk, C. Raderecht, and C. van Hoecke Ten years of experience with the trivalent split influenza vaccine, Fluarix™ Clin Drug Invest 22 11 2002 751 769
18. M.D. Decker, K.M. Edwards, M.C. Steinhoff, M.B. Rennels, M.E. Pichichero, and J.A. Englund Comparison of 13 acellular pertussis vaccines: adverse reactions Pediatrics 96 3 Part 2 1995 557 566